GSK Drops Out Of Auction For Pfizer's Consumer Health Unit
Executive Summary
The acquisition of Pfizer's consumer health business, which includes big named products such as Advil painkillers and Centrum multivitamins, has proven too big and too costly for GSK investors to stomach.
You may also be interested in...
Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche
Investors await news from Lilly on whether it will use repatriated cash for M&A; from Biogen on its Spinraza and gene therapy strategies in light of Novartis' AveXis deal; and from Amgen on pipeline programs and acquisitions as major products face new competition. Immuno-oncology combination updates are anticipated from Roche, plus guidance on how GSK will cope with Advair generics, HIV competition from Gilead and the cost of new drug launches is expected.
GSK Gains Clarity For Pharma Focus Through Novartis Consumer JV Buy
GSK removed some uncertainty about how much it could invest in pharma R&D and business development by purchasing Novartis' share of the firms' Consumer Healthcare Joint Venture. Now it can more accurately allocate capital as it prepares for battle in HIV and braces for Advair generics.
Deal Watch: Opportunity Knocks For Partnerships In Asia
ApolloBio signs on to take Inovio's HPV immunotherapy into China and Senju and Fosun sign China partnerships – all part of a wave of Chinese companies looking to bring innovative new medicines to the Greater China markets. Meanwhile, GSK signs on with Indian CRO Syngene.